Siemens Healthineers Forecast, price target & analysts
Siemens Healthineers Target price 2024 - Analyst rating & recommendation
Siemens Healthineers Classifications & Recommendation:
Siemens Healthineers Price Target
| Target Price | €59.72 |
| Price | €50.60 |
| Potential | 18.03% |
| Number of Estimates | 19 |
| 19 Analysts have issued a price target Siemens Healthineers 2025 . The average Siemens Healthineers target price is €59.72. This is 18.03% higher than the current stock price. The highest price target is €66.00 30.43% , the lowest is €50.00 1.19% . | |
| A rating was issued by 20 analysts: 17 Analysts recommend Siemens Healthineers to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Siemens Healthineers stock has an average upside potential 2025 of 18.03% . Most analysts recommend the Siemens Healthineers stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2029
18 Analysts have issued a sales forecast Siemens Healthineers 2025 . The average Siemens Healthineers sales estimate is €23.7b . This is 5.80% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €24.3b 8.57% , the lowest is €23.3b 4.39% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | €22.4b | 3.15% |
|---|---|---|
| 2025 | €23.7b | 5.80% |
| 2026 | €25.1b | 6.28% |
| 2027 | €26.6b | 5.94% |
| 2028 | €28.4b | 6.73% |
17 Analysts have issued an Siemens Healthineers EBITDA forecast 2025. The average Siemens Healthineers EBITDA estimate is €5.0b . This is 17.74% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €5.5b 29.44% , the lowest is €4.6b 8.53% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | €4.1b | 2.38% |
|---|---|---|
| 2025 | €5.0b | 23.26% |
| 2026 | €5.6b | 10.59% |
| 2027 | €6.2b | 11.90% |
| 2028 | €6.8b | 8.30% |
| 2029 | €7.3b | 8.05% |
EBITDA Margin
| 2024 | 18.30% | 0.75% |
|---|---|---|
| 2025 | 21.32% | 16.51% |
| 2026 | 22.18% | 4.03% |
| 2027 | 23.43% | 5.64% |
| 2028 | 23.78% | 1.49% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
13 Analysts have issued a Siemens Healthineers forecast for earnings per share. The average Siemens Healthineers <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is €2.11 . This is 21.26% higher than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is €2.35 35.06% , the lowest is €1.92 10.34% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | €1.74 | 28.89% |
|---|---|---|
| 2025 | €2.11 | 21.26% |
| 2026 | €2.53 | 19.91% |
| 2027 | €2.88 | 13.83% |
| 2028 | €3.25 | 12.85% |
P/E ratio
| Current | 29.14 | 23.74% |
|---|---|---|
| 2025 | 24.03 | 17.54% |
| 2026 | 20.03 | 16.65% |
| 2027 | 17.59 | 12.18% |
| 2028 | 15.57 | 11.48% |
Based on analysts' sales estimates for 2025, the Siemens Healthineers stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 2.97 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 2.39 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 3.14 | 6.27% |
|---|---|---|
| 2025 | 2.97 | 5.51% |
| 2026 | 2.79 | 5.91% |
| 2027 | 2.64 | 5.61% |
| 2028 | 2.47 | 6.30% |
P/S ratio
| Current | 2.53 | 4.78% |
|---|---|---|
| 2025 | 2.39 | 5.48% |
| 2026 | 2.25 | 5.91% |
| 2027 | 2.12 | 5.61% |
| 2028 | 1.99 | 6.31% |
Siemens Healthineers...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
